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BACKGROUND: Medication guides (MG) and manda-
tory patient package inserts (MPPI) are required with
some prescription medications.
OBJECTIVE: We sought to determine how many pa-
tients receive, read, and understand these mandated
materials.
DESIGN AND PARTICIPANTS: A total of 3,620 patients
were identiﬁed as ﬁlling prescriptions for isotretinoin or
selected estrogen products from February 2004 to
January 2005. Patients were surveyed to gauge receipt
and understanding of the MG for isotretinoin and the
MPPI for estrogen.
MEASUREMENTS AND MAIN RESULTS: A total of 500
patients completed the survey, with 186 (93%) of the
200 isotretinoin patients and 258 (86%) of the 300
estrogen patients reporting receipt of the MG/MPPI
with their most recent prescription. The majority of
respondents reported conﬁdence in their knowledge of
their medication (86% for isotretinoin and 75% for
estrogen). However, the mean score on 5 questions
assessing recognition of medication risks was only
slightly better than the score expected from guessing
(3.1 vs 2.5, P<.01 for both isotretinoin and estrogen).
CONCLUSIONS: Despite receiving the information and
reporting conﬁdence in medication knowledge, patients’
understanding of major risks with these medications
was poor. This ﬁnding highlights the need to develop
better risk communication strategies to improve the
safe and effective use of prescription medications.
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F
or medications such as all estrogens and drugs that pose a
serious or signiﬁcant public health risk, the U.S. Food and
Drug Administration (FDA) requires the distribution of written
medication information that had been approved by the FDA.
1,2
Forestrogen, thisinformationisknownasthemandatorypatient
package insert (MPPI).
3 For drugs with a high public health risk,
the information is called a medication guide (MG).
4,5
No evaluations have been conducted to assess distribution
and patient understanding of the MG/MPPI. The purpose of
this study was to assess the frequency with which patients
receive, read, and understand the MG for isotretinoin and
MPPI for selected estrogen products.
METHODS
Accutane®, Amnesteem®, and Sotret® were the selected brand-
named isotretinoin products, and Premarin® and Activella®
were the selected estrogen products. The MG/MPPI is included
within the drugs’ safety-sealed packaging, except in the case of
Premarin, for which the MPPI is distributed separately.
Prescription claims data from a pharmacy beneﬁts manager
(PBM) were used to identify patients for survey. Beneﬁciaries
from two participating PBM clients who were ≥18 years of age,
English speakers, with a prescription for one of the selected
drugs between February 2004 and January 2005 were eligible
for the study. Prescription claims were identiﬁed every 2 weeks.
Equal numbers of patients ﬁlling a prescription for each
brand-named product within each drug group were sought.
Available patient information included age, sex, patient rela-
tionship to the insured individual, geographic region, date of
prescription, and use of mail-order or retail pharmacy. For
those patients who participated in the survey, prescription
claims for all medications in the previous 6 months were also
obtained. Ten days were allowed for contact of all patients
from the end of each 2-week interval. This study was approved
by the Duke University Health System Institutional Review
Board.
Patient Survey
After giving consent, all patients were asked how conﬁdent
they were in their knowledge of their medication. A description
o ft h eM G / M P P Iw a sr e a dt oe a c hp a t i e n t .T h o s ew h o
remembered receiving the MG/MPPI were asked how thor-
oughly they read it, how helpful it was, and whether they had
received this information with previous prescriptions. Then 5
potential adverse effects/risks were read to each patient. For
each, the patient was asked whether the adverse effect/risk
could be associated with the use of their medication.
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98Patients who did not recall receiving the MG/MPPI with their
most recent prescription were asked if they had received it with
any of their previous prescriptions. Those who stated that they
had previously received it were asked the same questions listed
above. All remaining patients were only asked questions
pertaining to the 5 adverse effects/risks.
Design and Analysis
A survey sample size of 300 estrogen and 200 isotretinoin pa-
tients was sought.
Characteristics of respondents and nonrespondents were
compared using nonparametric tests. Responses were com-
pared between those patients reporting receipt of the MG/
MPPI with the most recent prescription and those who did not
receive it. Categorical variables were analyzed using chi-square
tests, and continuous variables were analyzed using Wilcoxon
two-sample tests. Nonparametric tests were used to make
comparisons among the overall number of correct responses to
the 5 risk questions between brand-named products within
each drug group and to the number of correct responses
expected from the use of a random guessing strategy.
A propensity score was developed to predict respondents
versus nonrespondents within each drug group using the fol-
lowing baseline variables: age, sex, primarily/secondarily in-
sured, time from ﬁlling of prescription to survey date, number
of previous prescriptions for same drug group, retail versus
mail-order, and survey quarter.
Generalized estimating equation models, using the estimat-
ed propensity scores as weights, were used to identify char-
acteristics associated with the number of correct responses to
the risk questions.
6 Variables, in addition to those listed above,
included completeness of reading of MG/MPPI with current
prescription, conﬁdence in drug knowledge, helpfulness of
MG/MPPI, past receipt of MG/MPPI, and past completeness
of reading of MG/MPPI. The relationship of predictor variables
to the estimated number of correct responses was summarized
using point estimates and 95% conﬁdence intervals. All
statistical comparisons were two-sided with P values <.05
considered statistically signiﬁcant.
RESULTS
A total of 3,620 patients were identiﬁed as ﬁlling a prescription
for one of the selected drugs. From these, 500 completed
surveys were obtained (300 from those receiving estrogen and
200 from those receiving isotretinoin). Reasons for nonre-
sponse included the following: no or incorrect telephone
number (1,554, 50%); unreachable (948, 30%); patient refused
to listen to the consent (505, 16%); patient unable to speak
English (52, 2%); patient refused to participate in the survey
(5/<1%); and miscellaneous other reasons (56, 2%).
Patients with Isotretinoin Prescriptions
A total of 172 (86%) of the 200 participants stated that they
were very conﬁdent/conﬁdent that they knew everything
necessary to safely take their isotretinoin. Of the 200 respon-
dents, 186 (93%) reported receiving the MG with their most
recent isotretinoin prescription. Patient characteristics and
survey responses are presented in Table 1. There were no
differences in the proportion of patients reporting receipt of the
MG among the 3 brand-named isotretinoin products (P=.3),
Table 1. Characteristics and Survey Responses of Responders Who
Recalled Receipt of Medication information
Characteristic Estrogen
(N=258)
Isotretinoin
(N=186)
Median age (25th, 75th percentile) 56 (53, 62) 31 (22, 41)
Female sex (%) 258 (100) 128 (69)
Relationship to insured
Self (%) 158 (61) 96 (52)
Spouse (%) 100 (39) 45 (24)
Dependent/others (%) 0 (0) 45 (24)
Median number of days between ﬁlling
of prescription and survey
(25th, 75th)
18 (15, 24) 18 (13, 24)
Mean number of previous
prescription ﬁlls of same drug class
in previous 6 months (SD)
3.99 (2.34) 2.27 (1.92)
New prescription for selected drug
group (%)
39 (15) 108 (58)
Number of patients who obtained
drug via mail order (%)
36 (14) 0
Number of patients who obtained
drug from a chain pharmacy (%)
219 (85) 160 (86)
Survey quarter
2004 Q1 (%) 112 (44) 36 (19)
2004 Q2 (%) 38 (15) 57 (31)
2004 Q3 (%) 45 (17) 20 (11)
2004 Q4 (%) 63 (24) 64 (34)
2005 Q1 (%) 0 (0) 9 (5)
Geographic region
West (%) 3 (1) 0
Northeast (%) 195 (76) 153 (82)
Southeast (%) 58 (22) 33 (18)
Midwest (%) 2 (<1) 0
Unknown (%) 0 0
Reported MG/MPPI receipt by brand
Accutane, % – 92
Amnesteem, % – 92
Sotret, % – 100
Activella, % 91 –
Premarin, % 81 –
Number of patients who read MG/
MPPI with most recent prescription
Completely, cover to cover (%) 72 (28) 77 (41)
Couple of complete sections (%) 30 (12) 30 (16)
One complete section (%) 6 (2) 1 (<1)
Skimmed (%) 52 (20) 28 (15)
Did not read any of the MG/MPPI (%) 96 (37) 49 (26)
Unknown (%) 2 (<1) 1 (<1)
Number of patients who read MG/
MPPI with previous prescription
N=222 N=104
Completely—cover to cover (%) 122 (55) 62 (60)
Couple of complete sections (%) 29 (13) 16 (15)
One complete section (%) 3 (1) 1 (1)
Skimmed (%) 36 (16) 13 (13)
Did not read any of the MG/MPPI (%) 26 (12) 12 (12)
Unknown (%) 6 (3) 0 (0)
Number of patients who reported MG/
MPPI as being very helpful/helpful
with most recent prescription (%)
115 (45) 129 (69)
MG Medication guide, MPPI medication patient package inserts, SD
standard deviation.
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who reported receipt of the MG and those who did not was the
median number of days between the ﬁlling of prescription and
survey (18 vs 22 days, P=.03).
The number and proportion of patients who correctly an-
swered each of the questions on the potential risks of iso-
tretinoin are presented in Table 2. The mean number of correct
responses was 3.1±1.1, which was only slightly better than the
anticipated score of 2.5 from pure guessing (P<.01). Results
fromthe propensity-weighted scoremodelpredicted thescoreto
increase by 0.6 in patients with a self-reported high level of
conﬁdence in their knowledge of isotretinoin and by 0.6 in
patients who recently read the entire MG. Of the 115 women
between the ages of 18–45, 4 (3.5%) did not report teratogenicity
as one of the potential risks of isotretinoin; 1 reported receipt of
the MG with the most recent prescription and 3 did not.
Patients with Estrogen Prescriptions
A total of 226 (75%) of the 300 participants stated that they
were very conﬁdent/conﬁdent that they knew everything
necessary to safely take their estrogen. Of the 300 respon-
dents, 258 (86%) reported receiving the MPPI with their most
recent prescription. Signiﬁcantly fewer patients reported re-
ceiving the MPPI with Premarin than with Activella (P=.02).
There were no differences in any of the collected characteristics
between those patients who reported receipt of the MPPI and
those who did not (Table 1).
The number and proportion of patients who correctly an-
swered each of the questions on potential risks of estrogen are
presented in Table 2. The mean number of correct responses
was 3.1±1.1, which was only slightly better than the anticipat-
ed score of 2.5 achieved from guessing (P<.01). The propensity-
weighted score model predicted an increase in score by 0.4 and
0.7 for patients who found the MPPI very helpful and for
patients who had previously read the MPPI, respectively.
DISCUSSION
Patient medication information is important, especially for
chronic medications that are self-administered. Adverse drug
events may be reduced among informed patients who are more
actively engaged in their own health care.
7,8 The MG/MPPI are
the only forms of patient medication information mandated by
the FDA. The high proportion of patients who said that they
received the MG/MPPI was encouraging, and the relatively
lower proportion of patients who reported receipt of the
Premarin MPPI indicates that inclusion of the MG/MPPI within
the drug packaging is important for patient receipt.
For written medication information to be effective, it must
read and understood. While it is encouraging that 94% of all
isotretinoin respondents knew of the teratogenic risk (96% of
those who received the MG with most recent prescription), 4
(3.5%) women were at potential risk from their lack of this
knowledge. A recent review by the FDA found 120 pregnancies
in patients taking isotretinoin in the year after initiation of the
System to Manage Accutane-Related Teratogenicity (SMART)
risk management program and 127 pregnancies reported in
the year before the initiation of the program.
9–11 Our results
indicate that, even with a risk management program that
includes the MG, some patients were unaware of the potential
risk.
For estrogen, knowledge gaps also existed. Fewer than half
of the respondents were aware of the myocardial infarction risk
despite its emphasis in the MPPI and extensive press coverage,
and only slightly more than half were aware of the risk of
uterine cancer.
12
A better process and format for communicating key medi-
cation information to patients appears necessary. Potential
solutions, such as the development of individualized written
information and patient counseling, should be more fully
explored.
Study limitations include the unavailability of more com-
plete demographic and medical information, including literacy
and socioeconomic status.
Conclusion
The content, presentation, and distribution of medication
information should be more rigorously evaluated to identify
feasible and cost-effective ways to more successfully educate
patients about their medications.
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Table 2. Reported Knowledge of Potential Adverse Effects
Question Number of correct
responses (%)
Isotretinoin (N=186)
Accutane/Amnesteem/Sotret
may cause bleeding
75 (40)
Accutane/Amnesteem/Sotret
may cause birth defects*
179 (96)
Accutane/Amnesteem/Sotret
may cause heart attacks
102 (55)
Accutane/Amnesteem/Sotret may
cause mental problems or suicide*
157 (84)
Accutane/Amnesteem/Sotret may
cause abnormal heart rhythms
67 (36)
Estrogen (N=258)
Premarin/Activella may cause infections 201 (78)
Premarin/Activella may increase the risk
of cancer of the uterus*
145 (56)
Premarin/Activella may increase the risk
of cancer of the brain
195 (76)
Activella should not be used during
pregnancy (N=136)*
126 (93)
Premarin may increase the risk of having
a heart attack (N=122)*
50 (41)
Premarin/Activella may cause abnormal
heart rhythms
77 (30)
*Risks that were included in medication guide MG or medication patient
package insert MPPI. Only the responses from patients who reported
receipt of the MG/MPPI with most recent prescription are included.
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